Optimization of treatment of depression with administration of ethylmethylhydroxypyridine succinate (Mexicor)

Medvedev V.E.; Frolova V.I.; Palin A.V.

doi:https://doi.org/10.17116/jnevro202312304178

Medvedev V.E.

Peoples Friendship University of Russian

SPIN RSCI: 2814-4975
Scopus AuthorID: 55545252400
ResearcherID: AAH-1849-2020
ORCID: 0000-0001-8653-596X

Frolova V.I.

RUDN University

ORCID: 0000-0003-2261-3812

Palin A.V.

RUDN University

ORCID: 0000-0002-9480-731X

Optimization of treatment of depression with administration of ethylmethylhydroxypyridine succinate (Mexicor)

Authors:

Medvedev V.E., Frolova V.I., Palin A.V.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(4): 78‑84

DOI: 10.17116/jnevro202312304178

Read: 3115 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Medvedev VE, Frolova VI, Palin AV. Optimization of treatment of depression with administration of ethylmethylhydroxypyridine succinate (Mexicor). S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(4):78‑84. (In Russ.)
https://doi.org/10.17116/jnevro202312304178

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)

Использование инфографики авторами научных работ

Close metadata

OBJECTIVE

To investigate the therapeutic efficacy and tolerability of Mexicor as an adjuvant in the treatment of depression with SSRI antidepressants.

MATERIAL AND METHODS

The study included 100 patients, aged 18—50 years, with verified depression of mild (n=32) or moderate (n=68) severity. Patients (n=50) of the main group, along with basic antidepressant therapy with SSRIs, received Mexicor at a dose of 600 mg/day, in the comparison group (n=50) — only SSRIs. Clinical-psychopathological, psychometric, using the HDRS-21 scale, CGI, HADS, fluency test of speech responses and the Stroop test, statistical research methods were used.

RESULTS

The reduction of depressive symptoms on the HDRS-21 scale, starting from the fourth week, was statistically significantly superior to that in the comparison group (p<0.001), the reduction in the severity of the condition on the CGI scale in the main group was also significantly greater than in the comparison group (17.3% and 9.6% respectively, p<0.05). A significant improvement in speech fluency was found in the main group (p<0.05). Adverse events in the main group were significantly less common (p<0.001).

CONCLUSION

Administration of Mexicor together with SSRIs leads to improved efficacy and tolerability of antidepressant therapy, and in the future, Mexicor may be recommended as an adjuvant in SSRI therapy for depression.

Keywords:

depression

treatment

antidepressants

SSRIs

Mexicor

Authors:

Medvedev V.E.

Peoples Friendship University of Russian

SPIN RSCI: 2814-4975
Scopus AuthorID: 55545252400
ResearcherID: AAH-1849-2020
ORCID: 0000-0001-8653-596X

Frolova V.I.

RUDN University

ORCID: 0000-0003-2261-3812

Palin A.V.

RUDN University

ORCID: 0000-0002-9480-731X

Received:

07.02.2023

Accepted:

15.03.2023

Close metadata

References:

Kotova OV, Frolova VI, Medvedev VE. Efficacy and tolerability of fluvoxamine (Rokona) in the treatment of depression in patients with cardiovascular pathology. Psychiatry and Psychopharmacotherapy. 2022;2:34-39. (In Russ.).
Medvedev VE. Anxiety and depression in COVID-19: treatment options. Neurology, Neuropsychiatry, Psychosomatics. 2021;13(2):111-116. (In Russ.). https://doi.org/10.14412/2074-2711-2021-2-111-116
Kennedy SH, et al. Treating depression effectively. J Clin Psychiatry. 2004;78(suppl 3):44-49.
Stahl SM. Serotonin antagonism and reuptake inhibition; pharmacology and physiology of CNS serotonin housekeeping. Int J Neuropsychopharmacology. 2004:7(suppl 1):117.
Cowen PJ. New drugs, old problems. Revisiting... Pharmacological management of treatment-resistant depression. Advances in Psychiatric Treatment. 2005;11.
Depont F, et al. Treatment — Resistant Depression. Acta Psychiatr Scand. 2003;108:24-31.
Medvedev VE. Efficacy and tolerability of contemporary antidepressants: results of network meta-analyses and Russian experience. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2018;118(11):109-117. (In Russ.). https://doi.org/10.17116/jnevro2018118111109
Medvedev VE, Kardashyan RA, Frolova VI, et al. Investigation of the efficiency of various antidepressant replacement regimens in the development of SSRI-induced apathy syndrome. Neurology, Neuropsychiatry, Psychosomatics. 2020;12(2):48-56. (In Russ.). https://doi.org/10.14412/2074-2711-2020-2-48-56
Alekhnovich AV, Ilyashenko KK, Yelkov AN, et al. Comparative assessment of the clinical effectiveness of antihypoxants in patients with acute poisoning with psychotropic drugs. General Resuscitation. 2009;5(1):58. (In Russ.). https://doi.org/10.15360/1813-9779-2009-1-58
Kotova OV, Zuykova NL, Palin AV, et al. Psychopathological disorders in chronic cerebral ischemia: possibilities of prevention. Lechaschi Vrach. 2021;5(24):22-26. (In Russ.). https://doi.org/10.51793/OS.2021.15.98.005
Akarachkova ES, Baidauletova AI, Belyaev AA, et al. Stress: causes and consequences, treatment and prevention: Clinical guidelines. SPb.: Scythia-print; M.: Profmedpress; 2020;138. (In Russ.).
Medvedev VE. Nootropic drugs and neuroprotectors in the treatment of mental disorders: Textbook. M. 2015;152. (In Russ.).
Medvedev VE, Korovyakova EA, Frolova VI, Gushanskaya EV. Antidepressant therapy in patients with cardiovascular diseases. Neurology, Neuropsychiatry, Psychosomatics. 2019;11(1):131-140. (In Russ.). https://doi.org/10.14412/2074-2711-2019-1-131-140
Medvedev VE. Mexidol in psychiatric practice. Psychiatry and psychopharmacotherapy. 2010;4:18-21. (In Russ.).
Gladchenko MP, Artyushkova EB, Frolova OG, et al. Experimental study of the possibility of reducing the cardiotoxic effects of Mitomycin C using the immobilized form of Mitomycin C «and cytoprotector Man and His Health. 2022;25(1):45-53. (In Russ.). https://doi.org/10.21626/vestnik/2021-3/06
Kalenikova EI, Tokareva OG, Kulyak OJ, et al. Comparison of cardioprotective efficacy of coenzyme Q10 and mexicor in experimental myocardastatic ischemia. Experimental and clinical pharmacology. 2015;78(6):12-14. (In Russ.).
Kotlyarov AA, Sernov LN. Features of combined use of mexicor with certain antiarrhythmic drugs in acute coronary artery occlusion in an experiment. Russian Journal of Cardiology. 2003;(5):77-82. (In Russ.).
Statsenko ME, Turkina SV. Hepatoprotective effects of mexicor® in the treatment of patients with chronic heart disease and type 2 diabetes mellitus. Archive of Internal Medicine. 2013;(3):63-69. (In Russ.).
Voronina TA. Antioxidant Mexidol. Main effects and mecha-nism of action. Psychopharmacology and Biology. Narcology. 2001;1:2-12. (In Russ.).
Voronina TA. Mexidol: Major neuropsychotropic effects and mechanism of action. Pharmateka. 2009;6:28-31. (In Russ.).
Kosenko VG, Karagezyan EA, Luneva LV, Smolenko LF. Use of mexidol in psychiatric practice. Journal of Neurology and Psychiatry im. S.S. Korsakov. 2006;6:38-41. (In Russ.).
Piven BN, Vasilyeva VYa, Stroganova IM. Clinical introduction of Mexidol into the practice of treating patients with exogenous-organic brain lesions. Barnaul. 2000. (In Russ.).
Sariev AK, Davydova IA, Neznamov GG, et al. Relationship between the glucuronoconjugation of mexidol and its therapeutic effects in patients with organic CNS damage. Exp. and Wedge. Pharmacology. 2001;3:17-21. (In Russ.).
Simutis IS, Boyarinov GA, Mukhin AS, et al. Combined antihypoxic therapy of severe blood loss. Journal of MediAl. 2018;(1):68-69. (In Russ.).
Soloviev NA, Yasnetsov VV. Experimental and clinical study of the action of mexidol in some pathology. Elucidation of possible localization and mechanism of action. Bulletin of Experimental Biology and Medicine. 2006;App. 1B:230-241. (In Russ.).
Fedin AI, et al. Use of the antioxidant mexidol in patients with acute cerebrovascular accident. Method. river. M. 2002. (In Russ.).
Chumakov MV, Efremov AA, Zvereva NYu, et al. Oxidative stress and methods of correction in patients with acute disorders coronary circulation in the perioperative period of direct myocardial revascularization. General resuscitation. 2008;4(4):26. (In Russ.). https://doi.org/10.15360/1813-9779-2008-4-26
Smirnova IN, et al. Clinical efficacy and antioxidant activity of Mexidol in chronic cerebrovascular diseases . Atmosphere. Nervous Diseases. 2006;1:33-36. (In Russ.).
Shevchenko LA, Krivosheev RV, Evdokimov VA. On the therapeutic effectiveness of the use of mexidol in the integrated treatment of patients suffering from brain strokes. International Neurological Journal. 2006;2(6):88-92. (In Russ.).
Rosselli MA, Alfredo S, Marquez J, et al. A cross-linguistic comparison of verbal fluency tests. The International Journal of Neuroscience. 2002;112:759-776. https://doi.org/10.1080/00207450290025752
Stroop JR. Studies of interference in serial verbal reactions. Journal of Experimental Psychology. 1935;18(6):643-662. hdl:11858/00-001M-0000-002C-5ADB-7